134 Coolidge Ave
Tel: (603) 490-9117
13 articles with SQZ Biotech
Marc Schegerin, MD and Sapna Srivastava, PhD join as new board members and Micah Zajic as Chief Business Officer
10/15/2020Find out which life sciences companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.
SQZ Biotech Appoints Paul Bolno, MD to Board of Directors and Kai Wucherpfennig, MD, PhD to Scientific Advisory Board
SQZ Biotechnologies (SQZ), a clinical stage cell therapy company developing novel treatments for multiple therapeutic areas, today announced the appointments of Paul Bolno, MD, to its board of directors, and Kai Wucherpfennig, MD, PhD, to its scientific advisory board. Dr. Bolno is the chief executive officer of Wave Life Sciences and brings over 15 years of experience in both corporate and scientific leadership. Dr. Wu
SQZ Biotechnologies, a cell therapy company developing novel treatments for multiple therapeutic areas, announced that Armon Sharei, PhD, chief executive officer, will be presenting at the following upcoming virtual investor conferences
Financing Supports Ongoing Phase 1 Trial of SQZ APC Platform in HPV+ Tumors and Advancement of SQZ AAC Platform towards an Investigational New Drug Application
“We are thrilled to have the support of both our new and long-standing investors who believe in SQZ and our potential to create impactful therapies for patients,” said Teri Loxam, SQZ’s chief financial officer.
SQZ Biotechnologies (SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will present a corporate overview at the UBS Virtual Global Healthcare Conference on May 18, 2020 at 10:50am EST.
2/3/2020It was another busy week for clinical trial updates. Here’s a look.
Armon Sharei, chief executive officer of SQZ Biotech, said 2020 is going to be an exciting year for the company as it anticipates having clinical data available from its first trial by the end of this year.
10/28/2019Although the clinical trial news last week was dominated by the stunning reversal of Biogen and Eisai’s clinical trials of aducanumab for Alzheimer’s disease, there was plenty of other trial news. Here’s a look.
8/9/2019Biopharma companies strengthen their senior leadership teams and boards of directors.
4/18/2019In the first quarter of 2019, more than 30 life science companies* announced expansions, new locations, increased funding, new trial and product launches and various other news pointing to a growing industry.
SQZ Biotech is on a roll. Months after securing $72 million in a Series C financing round and expanding a developmental agreement with pharma giant Roche worth up to $1 billion, the company is now expanding its footprint in Watertown, Mass.